PubRank

Jörg H W Distler

Author PubWeight™ 87.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis 2012 2.66
2 Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012 2.65
3 MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010 2.53
4 Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011 2.05
5 Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004 1.88
6 The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2013 1.57
7 Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011 1.56
8 Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004 1.53
9 Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007 1.38
10 Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009 1.36
11 Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008 1.33
12 β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012 1.25
13 A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 2011 1.24
14 Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008 1.20
15 IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2011 1.18
16 Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum 2007 1.17
17 Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet 2012 1.17
18 Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010 1.16
19 Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008 1.16
20 Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007 1.14
21 WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 2012 1.08
22 The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 2008 1.08
23 Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011 1.07
24 Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009 1.06
25 Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009 1.01
26 Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011 1.00
27 Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly 2010 0.98
28 Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012 0.96
29 The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis 2007 0.96
30 CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 2010 0.95
31 The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun 2012 0.95
32 Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012 0.95
33 Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med 2011 0.95
34 The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009 0.95
35 Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011 0.94
36 The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010 0.94
37 Inflammation: Microparticles and their roles in inflammatory arthritides. Nat Rev Rheumatol 2010 0.93
38 Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012 0.93
39 Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013 0.92
40 Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2012 0.91
41 Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. Biochim Biophys Acta 2012 0.91
42 The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 2013 0.91
43 Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 2012 0.90
44 Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012 0.89
45 Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012 0.88
46 A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis. Arthritis Rheum 2013 0.87
47 Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012 0.86
48 Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012 0.85
49 Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012 0.85
50 Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012 0.85
51 The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011 0.85
52 Morphogen pathways in systemic sclerosis. Curr Rheumatol Rep 2013 0.84
53 Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies? Exp Dermatol 2013 0.84
54 Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2012 0.83
55 The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012 0.83
56 Autophagy: a key pathway of TNF-induced inflammatory bone loss. Autophagy 2013 0.83
57 Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. J Cell Mol Med 2009 0.83
58 Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010 0.83
59 Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 2012 0.83
60 Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Res Ther 2012 0.83
61 Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012 0.83
62 Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009 0.82
63 Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis 2012 0.82
64 New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis 2013 0.81
65 The Fra-2 transgenic mouse model of systemic sclerosis. Vascul Pharmacol 2012 0.81
66 Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert Rev Clin Immunol 2011 0.80
67 Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. J Bone Miner Res 2013 0.80
68 A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther 2014 0.80
69 The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Arthritis Rheumatol 2014 0.80
70 Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? Ann Rheum Dis 2007 0.80
71 EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis 2011 0.80
72 Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med 2015 0.79
73 Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum 2009 0.79
74 Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. Arthritis Rheum 2010 0.79
75 Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis 2013 0.79
76 JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012 0.79
77 Vascular alterations upon activation of TGFbeta signaling in fibroblasts--implications for systemic sclerosis. Arthritis Res Ther 2010 0.78
78 Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol 2014 0.78
79 Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012 0.78
80 Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Ann Rheum Dis 2012 0.78
81 Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr Rheumatol Rep 2011 0.78
82 Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012 0.77
83 Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013 0.77
84 Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Curr Opin Pharmacol 2013 0.77
85 Subtractive hybridization. Methods Mol Med 2007 0.76
86 Changing paradigms in spondylarthritis: the myofibroblast signature. Arthritis Rheum 2013 0.76
87 Deciphering the pro-fibrotic phenotype of fibroblasts in systemic sclerosis. Exp Dermatol 2014 0.75
88 International rheumatology networking: The 2008 American College of Rheumatology/European League Against Rheumatism exchange program. Arthritis Rheum 2009 0.75
89 TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Ann Rheum Dis 2012 0.75
90 Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol 2015 0.75
91 Corrigendum: Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 2016 0.75